Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

TOThomas OllilaNGNatalie S. GroverYTYun Kyoung Tiger

Discussion

Loading...

Member takes

Overview

Observational analysis identified high LDH and ferritin as risk factors for CRS and NT in patients with aggressive B-cell lymphomas receiving bispecific antibodies.

Key Points

  • 79 of 244 patients (32%) experienced any grade cytokine release syndrome after receiving bispecific antibodies.
  • Increased incidence of any grade neurotoxicity was observed in patients with high ferritin (>336 ng/mL).
  • Analysis of a shared database across 14 institutions assessed incidence and risk factors for cytokine release syndrome and neurotoxicity.
  • Findings suggest monitoring for high LDH and ferritin levels may help identify patients at risk during treatment ramp-up.

Cite This Study

Ollila et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e358https://doi.org/10.1182/blood-2025-960
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.2025
  2. 2Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience2025
  3. 3Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort2025
  4. 4Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper2025
  5. 5Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma2025